Synergy Pharmaceuticals Inc  

(Public, NASDAQ:SGYP)   Watch this stock  
Find more results for OTC:SGYP
2.74
+0.02 (0.74%)
After Hours: 2.74 0.00 (0.00%)
Oct 20, 5:02PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.65 - 2.75
52 week 2.45 - 6.70
Open 2.70
Vol / Avg. 635,993.00/1.05M
Mkt cap 257.84M
P/E     -
Div/yield     -
EPS -0.82
Shares 94.80M
Beta 0.02
Inst. own 31%
Nov 10, 2014
Q3 2014 Synergy Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Aug 11, 2014
Q2 2014 Synergy Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -155.58% -112.99%
Return on average equity -205.36% -154.96%
Employees 25 -
CDP Score - -

Address

SUITE 2012, 420 LEXINGTON AVENUE
NEW YORK, NY 10170
United States - Map
+1-212-2970010 (Phone)
+1-212-2970019 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company�s lead product candidate is plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic constipation (CC), and constipation-predominant-irritable bowel syndrome (IBS-C). It is also developing SP-333, the second generation GC-C receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis (UC). The Company�s active pharmaceutical ingredients (APIs) and the final formulated drug products are manufactured for it by third party contractors. As of December 31, 2011, the Company was developing plecanatide, a synthetic hexadecapeptide designed to mimic the actions of the GI hormone uroguanylin, for the treatment of CC and IBS-C. Plecanatide is an agonist of GC-C receptor.

Officers and directors

Gary S. Jacob Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 67
Bio & Compensation  - Reuters
Bernard F. Denoyer CPA Senior Vice President - Finance, Secretary, IR Contact Officer
Age: 67
Bio & Compensation  - Reuters
Paul Eng Ph.D. Senior Vice President - Drug Development
Bio & Compensation  - Reuters
Marino Garcia Senior Vice President - Corporate Development
Bio & Compensation  - Reuters
Kunwar Shailubhai Ph.D. Chief Scientific Officer
Age: 57
Bio & Compensation  - Reuters
Thomas H. Adams Jr., Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
John P. Brancaccio Independent Director
Age: 67
Bio & Compensation  - Reuters
Alan F. Joslyn Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Christopher McGuigan Ph.D Independent Director
Age: 56
Bio & Compensation  - Reuters
Melvin K. Spigelman M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters